This is just in time for @PayorDieFilm premiering March 11 and will shine a light on the huge amount of suffering patients have endured for years due to the cost of insulin.
You try to fix one, they point to the other broken parts and say it’s not going to work because so much else is broken.
You can’t fix it all because the opposition to change will naturally now come from all quarters.
It’s just very difficult. And needs enormous will.
If insulin can be expensive then you know it can happen to any drug old or new. If we understand why insulin is expensive you also understand many of the factors involved.
Updated mSMART recommendations for treatment of myeloma posted on mSMART.org#MedTwitter
1/ New for relapsed myeloma, clear recommendations based on type of Triple-Class refractory. We define 3 types. @Rfonsi1@myelomaMD@MorieGertz
2/ New for Relapsed Myeloma - Approach to first relapse based on refractoriness to Len and Anti-CD38.
3/ We feel that bispecific and CAR-T approvals be based on refractoriness to specific drugs and drug classes and not be restricted by lines of therapy because myeloma can be refractory to all major drugs even within 2 lines.
Maximum tolerated dose was an idea used with conventional cytotoxic agents. It’s time has passed.
We should now strive for minimum effective dose or optimal effective dose.
Even with targeted therapies and biologic therapies we have found years after drug approval that the original approved dose was too high and caused unnecessary toxicity.